Elicio Therapeutics (ELTX) Invested Capital (2020 - 2026)

Elicio Therapeutics has reported Invested Capital for 7 years, with the latest figure at -$1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital fell 116.14% year-over-year to -$1.4 million; the trailing twelve-month figure through Mar 2026 stood at -$1.4 million (down 116.14% YoY), and the FY2025 full-year result was $11.6 million, up 202.86% from the prior year.
• Invested Capital for Q1 2026 stood at -$1.4 million, down from $11.6 million in the prior quarter.
• The five-year high for Invested Capital was $23.6 million in Q2 2023, with the low at -$109.9 million in Q1 2023.
• Historically, Invested Capital has averaged -$24.8 million across 5 years, with a median of -$1.4 million in 2026.
• Annual changes were most pronounced in 2022 — Invested Capital slumped 248.34% — and 2025, when it soared 816.34%.
• Elicio Therapeutics' Invested Capital stood at -$102.1 million in 2022, then jumped by 111.13% to $11.4 million in 2023, then plunged by 199.46% to -$11.3 million in 2024, then jumped by 202.86% to $11.6 million in 2025, then sank by 112.35% to -$1.4 million in 2026.
• The last three Invested Capital figures came in at -$1.4 million (Q1 2026), $11.6 million (Q4 2025), and $3.8 million (Q3 2025), per Business Quant data.